Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A blood-based biomarker panel for non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis

4 Nov 2024

Abstract excerpt

The current diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe form, metabolic dysfunction-associated steatohepatitis (MASH), is suboptimal. Here, we recruited 700 individuals, including 184 from Hong Kong as a discovery cohort and 516 from San Diego, Wenzhou, and Hong Kong as three validation cohorts. A panel of 3 parameters (C-X-C motif chemokine ligand 10 [CXCL10],...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diet, Metabolism, and Disease
Share to Liver Disease Diagnosis and Treatment
Share to Pancreatitis Pathology and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39500327
DOI: 10.1016/j.cmet.2024.10.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A blood-based biomarker panel for non-invasive diagnosis of metabolic dysfunction-associated steatohepatitisPMID 39500327Read ↗

Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management.Semantic proximity Read ↗

Phenotypes of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma.Semantic proximity Read ↗

Polymorphisms Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease Influence the Progression of End-Stage Liver DiseaseSemantic proximity Read ↗

Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtypingSemantic proximity Read ↗

Diagnosis and Staging of Metabolic Dysfunction-Associated Steatotic Liver Disease Using Biomarker-Directed Aptamer PanelsSemantic proximity Read ↗

Identification and validation of efferocytosis-related biomarkers for the diagnosis of metabolic dysfunction-associated steatohepatitis based on bioinformatics analysis and machine learningSemantic proximity Read ↗

Novel subtypes of metabolic associated steatotic liver disease linked to clinical outcomes: implications for precision medicine.Semantic proximity Read ↗

Evaluation of MARC1 Variants and Extracellular Vesicle Cytokeratin-18 as Predictive Biomarkers in a group of Egyptian MASLD and MASH patientsSemantic proximity Read ↗

Machine Learning Enables Single-Score Assessment of MASLD Presence and SeveritySemantic proximity Read ↗

Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome AnalysisSemantic proximity Read ↗

Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated alcohol‑related liver disease represent distinct clinical phenotypes and fibrosis risks: insights from a population-based Polish cohort.Semantic proximity Read ↗

[Precise clinical classification of metabolic associated fatty liver disease].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.